Trial intelligence / Profile preview

12-week randomized study of AVE0010 in drug-naïve type 2 diabetes

2007-005887-29Phase 3Completed

Sponsor
Sanofi
Start
Apr 2008
Modality
Peptides
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing AVE0010 two-step titration with Placebo (2 arms). Primary endpoint: HbA1c absolute change at week 12. Started Apr 2008; status: completed.

02

Drugs

lixisenatide
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on 2007-005887-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-005887-29.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call